|
 Moncef Slaoui, chief adviser to the U.S. government's Operation Warp
Speed initiative, said he has not yet met with Biden, who last week
criticized the Trump administration's vaccine distribution plan.
"We really look forward to it because actually things have been
really very appropriately planned," Slaoui said in an interview with
CBS' "Face the Nation."
Biden said on Friday his team had not seen a detailed outline from
the Trump administration to distribute a vaccine to states, which he
called an expensive and difficult process.
"There is no detailed plan that we've seen, anyway, as to how you
get the vaccine out of a container, into an injection syringe, into
somebody's arm," Biden said.
Slaoui said the government's plan relies on state health agencies to
deliver the vaccine.
"I think the plans are there and I feel confident that once we will
explain it, everything in detail. I hope the new transition team
will understand that things are well planned," he told the CBS
program.
It was not clear if Biden would attend the meeting himself.
The United States is struggling with a resurgence of the virus, with
record infections and a daily death toll that has exceeded 2,000 in
recent days. More than 281,000 Americans have died from the COVID-19
disease, according to a Reuters tally.
President Donald Trump's refusal to acknowledge his loss to Biden in
the Nov. 3 presidential election caused a delay in the transition
process that allowed White House health advisers to communicate with
the new Biden health advisory team.
Biden was due to announce members of his public health team this
week.
[to top of second column] |
VACCINE MANUFACTURING DELAY
First-responders, health care workers and nursing home residents will be the
first groups to receive the vaccine once the U.S. Food and Drug Administration
approves it, which is expected in the next week or two. The FDA's outside
advisers are scheduled to meet on Thursday to review Pfizer's emergency use
application for its vaccine.
FDA approval does not assure smooth sailing. Slaoui told CNN's "State of the
Union" the vaccine manufacturing effort has been more complicated and difficult
than expected.
"We probably are six or eight weeks later than an ideal scenario, where we had
100 million doses by the end of this year," he said. "But we are not far."
The people most susceptible to coronavirus would start seeing the impact of the
vaccine in January or February, Slaoui said on CBS.
"But on a population basis, for our life to start getting back to normal, we're
talking about April or May," he said.
With the winter holiday season approaching, U.S. health experts have been
pleading with Americans to not let up on their coronavirus safety protocols -
wearing masks, social distancing and avoiding large gatherings.
Dr. Deborah Birx, who serves on the White House coronavirus task force, told
NBC's "Meet the Press" that public health officials have had to battle incorrect
messages from the Trump administration about masks and other mitigation
measures.
"I want to be very frank to the American people. The vaccine is critical. But
it's not going to save us from the current surge," she said. "Only we can save
us from this current surge."
(Reporting by Doina Chiacu; Editing by Lisa Shumaker and Paul Simao)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
